Opus Genetics, Inc.·4

Jul 27, 4:08 PM ET

YERXA BENJAMIN R 4

4 · Opus Genetics, Inc. · Filed Jul 27, 2026

Research Summary

AI-generated summary of this filing

Updated

Opus Genetics (IRD) President Benjamin R. Yerxa Sells Shares

What Happened
Benjamin R. Yerxa, President and a director of Opus Genetics (IRD), reported a sale of 7,429 shares on 2026-07-23 at $2.97 per share, generating $22,064. This was a sale (code S) and not a buy—such sales are often routine rather than a directional signal.

Key Details

  • Transaction date and price: 2026-07-23 — 7,429 shares @ $2.97 each (total ~$22,064).
  • Shares owned after transaction: Not specified in the summary provided (not reported here).
  • Footnote: The shares were sold automatically to satisfy tax withholding obligations arising from the vesting/settlement of restricted stock units (RSUs). This was an automatic, non‑discretionary sale.
  • Filing timeliness: Form 4 filed 2026-07-27; this filing appears timely (within the standard two business‑day reporting window).

Context
This transaction reflects an automatic tax-withholding sale related to RSU vesting, per the filer’s footnote, not an active trading decision. For retail investors, purchases by insiders can be more informative about confidence in the company; routine withholding sales are common and typically do not indicate a change in insider sentiment.

Insider Transaction Report

Form 4
Period: 2026-07-23
YERXA BENJAMIN R
DirectorPresident
Transactions
  • Sale

    Common Stock

    [F1]
    2026-07-23$2.97/sh7,429$22,064704,106 total
Footnotes (1)
  • [F1]The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person.
Signature
/s/ Amy Rabourn, by Power of Attorney|2026-07-27

Documents

1 file
  • 4
    form4.xmlPrimary

    FORM 4